AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 4072589 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O and oxygen
Number of subjects: 81
Study 4072589 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O, oxygen, and 0.25% halothane
Number of subjects: 81
Study 4072589 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O, oxygen, and 0.5% halothane
Number of subjects: 81
Study 4072589 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O, oxygen, and 0.5% enflurane
Number of subjects: 81
Study 4072589 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O, oxygen, and 1% enflurane
Number of subjects: 81
Study 4072589 — intervention group
Group type: COMPARATOR
Intervention: N2O alone
Number of subjects: 81
Study 4072589 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O, oxygen, and halogenated agents
Number of subjects: 81
Study 31623675 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin C supplementation (500 mg daily during the last 2 cycles)
Number of subjects: 20
Study 31623675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29498347 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 supplementation
Number of subjects: 36
Study 29498347 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 supplementation with pre-cooling
Number of subjects: 36
Study 29498347 — intervention group
Group type: COMPARATOR
Intervention: Pre-cooling
Number of subjects: 36
Study 29498347 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study 26645413 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT (LDCT) screening
Number of subjects: 4055
Study 24362951 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVE) + Exemestane (EXE) (10 mg/day + 25 mg/day)
Number of subjects: 137
Study 24362951 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) + Exemestane (EXE) (placebo + 25 mg/day)
Number of subjects: 137
Study 24362951 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVE) + Exemestane (EXE)
Number of subjects: 137
Study 24362951 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) + Exemestane (EXE)
Number of subjects: 137
Study 22863207 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care with moderate intensity aerobic exercise (12-week walking program at 60-75% HRmax)
Number of subjects: 19
Study 22863207 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care with moderate intensity aerobic exercise
Number of subjects: 19
Study 22863207 — intervention group
Group type: COMPARATOR
Intervention: Usual care (sedentary)
Number of subjects: 19
Study 20211040 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins (vitamins B-complex, C and E)
Number of subjects: 959
Study 20211040 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal multivitamin supplements
Number of subjects: 959
Study 20211040 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins
Number of subjects: 959
Study 20211040 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A plus beta-carotene
Number of subjects: 959
Study 20211040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 959
Study 18575008 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized bacitracin/colimycin
Number of subjects: 14
Study 18575008 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 14
Study 18575008 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal endoscopic findings
Number of subjects: 14
Study 18575008 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 questionnaire
Number of subjects: 14
Study 15831584 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV vaccine
Number of subjects: 0
Study 15831584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12356611 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine
Number of subjects: 0
Study 12356611 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine combined with interferon alfa
Number of subjects: 0
Study 12356611 — intervention group
Group type: EXPERIMENTAL
Intervention: Bufotoxin combined with interferon alfa
Number of subjects: 0
Study 12356611 — intervention group
Group type: EXPERIMENTAL
Intervention: Kurorinone
Number of subjects: 0
Study 10613092 — intervention group
Group type: EXPERIMENTAL
Intervention: BiliBed
Number of subjects: 22
Study 10613092 — intervention group
Group type: COMPARATOR
Intervention: Conventional phototherapy
Number of subjects: 22
Study 8540719 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg daily for 6 days)
Number of subjects: 20
Study 8540719 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg every 8 h for 5 days plus omeprazole)
Number of subjects: 20
Study 8540719 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin with omeprazole
Number of subjects: 20
Study 1789861 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic test with unknown accuracy parameters
Number of subjects: 0
Study 6848681 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 179
Study 6848681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 31669837 — intervention group
Group type: EXPERIMENTAL
Intervention: Saffron (60 mg/day)
Number of subjects: 50
Study 31669837 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (100 mg/day)
Number of subjects: 50
Study 29505140 — intervention group
Group type: EXPERIMENTAL
Intervention: PE-formula
Number of subjects: 50
Study 29505140 — intervention group
Group type: COMPARATOR
Intervention: S-formula
Number of subjects: 50
Study 26387973 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% minoxidil topical foam (5% MTF)
Number of subjects: 45
Study 26387973 — intervention group
Group type: COMPARATOR
Intervention: Placebo topical foam (plaTF) until week 24, followed by 5% MTF until week 104
Number of subjects: 45
Study 25000669 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride dentifrice
Number of subjects: 116
Study 25000669 — intervention group
Group type: COMPARATOR
Intervention: Marketed sodium fluoride dentifrice (negative control)
Number of subjects: 116
Study 23052313 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (SXT) on Mueller-Hinton agar (MHA) with defibrinated horse blood and 20 mg/liter β‐NAD (MHF)
Number of subjects: 200
Study 23052313 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (SXT) on MHA with sheep blood (MHS)
Number of subjects: 200
Study 23052313 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (SXT) on MHA alone (MHA)
Number of subjects: 200
Study 23052313 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (SXT) on MHA with horse blood (MHBA)
Number of subjects: 200
Study 23052313 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (SXT) on MHA with lysed horse blood (MHLHBA)
Number of subjects: 200
Study 20435188 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril + CCB
Number of subjects: 2122
Study 17420182 — intervention group
Group type: EXPERIMENTAL
Intervention: Male latex condom
Number of subjects: 108
Study 17420182 — intervention group
Group type: EXPERIMENTAL
Intervention: Female polyurethane condom
Number of subjects: 108
Study 17420182 — intervention group
Group type: COMPARATOR
Intervention: Mechanical problems (both condoms)
Number of subjects: 108
Study 17420182 — intervention group
Group type: COMPARATOR
Intervention: Correct use with no problems (both condoms)
Number of subjects: 108
Study 16379508 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 21
Study 11927527 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL
Number of subjects: 898
Study 9797517 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.1 mg.kg‐1
Number of subjects: 0
Study 9797517 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.15 mg.kg‐1
Number of subjects: 0
Study 9797517 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg.kg‐1
Number of subjects: 0
Study 9797517 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.1 mg.kg‐1 with spontaneous recovery
Number of subjects: 0
Study 9797517 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.1 mg.kg‐1 with neostigmine at 10% recovery
Number of subjects: 0
Study 9797517 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.1 mg.kg‐1 with neostigmine at 25% recovery
Number of subjects: 0
Study 9797517 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.15 mg.kg‐1 with spontaneous recovery
Number of subjects: 0
Study 9797517 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.15 mg.kg‐1 with neostigmine at 10% recovery
Number of subjects: 0
Study 9797517 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.15 mg.kg‐1 with neostigmine at 25% recovery
Number of subjects: 0
Study 9797517 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg.kg‐1 with spontaneous recovery
Number of subjects: 0
Study 9797517 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg.kg‐1 with neostigmine at 10% recovery
Number of subjects: 0
Study 9797517 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg.kg‐1 with neostigmine at 25% recovery
Number of subjects: 0
Study 9797517 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine
Number of subjects: 0
Study 8583056 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-rung grip test
Number of subjects: 0
Study 8583056 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid exchange grip test
Number of subjects: 0
Study 8583056 — intervention group
Group type: EXPERIMENTAL
Intervention: Model for categorizing patients
Number of subjects: 0
Study 2663868 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrective orthopaedic shoes
Number of subjects: 129
Study 2663868 — intervention group
Group type: EXPERIMENTAL
Intervention: Helfet heel-cup
Number of subjects: 129
Study 2663868 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-molded plastic insert
Number of subjects: 129
Study 2663868 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 129
Study 241599 — intervention group
Group type: EXPERIMENTAL
Intervention: Alclofenac 1 g t.d.s.
Number of subjects: 11
Study 241599 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 11
Study 31926224 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief CBT (5 sessions, 5.5 hours)
Number of subjects: 313
Study 31926224 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard CBT (10 sessions, 15 hours)
Number of subjects: 313
Study 31926224 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief CBT
Number of subjects: 313
Study 31926224 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard CBT
Number of subjects: 313
Study 31926224 — intervention group
Group type: EXPERIMENTAL
Intervention: Both brief and standard CBT
Number of subjects: 313
Study 31926224 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 313
Study 30715779 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient powders (MNPs)
Number of subjects: 829
Study 30715779 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurturant home environment
Number of subjects: 829
Study 30715779 — intervention group
Group type: COMPARATOR
Intervention: Inflammation presence
Number of subjects: 829
Study 28493923 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 minute deep breathing
Number of subjects: 0
Study 28493923 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Number of subjects: 0
Study 28493923 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 26181338 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body point-of-care ultrasound curriculum (Focused periOperative Risk Evaluation Sonography Involving Gastroabdominal Hemodynamic and Transthoracic ultrasound)
Number of subjects: 42
Study 26181338 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathology assessment training
Number of subjects: 42
Study 26181338 — intervention group
Group type: COMPARATOR
Intervention: Clinical examinations post-training
Number of subjects: 42
Study 23169695 — intervention group
Group type: EXPERIMENTAL
Intervention: GH
Number of subjects: 12
Study 23169695 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 12
Study 23169695 — intervention group
Group type: EXPERIMENTAL
Intervention: GH+Testosterone
Number of subjects: 12
Study 21763198 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 32
Study 21763198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 19166395 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 426
Study 19166395 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 426
Study 17114560 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam syrup (0.5 mg/kg)
Number of subjects: 139
Study 17114560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 15233550 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Hz whole body vibration
Number of subjects: 10
Study 15233550 — intervention group
Group type: COMPARATOR
Intervention: Control (absence of vibration)
Number of subjects: 10
Study 11764398 — intervention group
Group type: EXPERIMENTAL
Intervention: 188Re irradiation using an angioplasty balloon
Number of subjects: 26
Study 11764398 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 26
Study 9235377 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone-containing solutions
Number of subjects: 58
Study 9235377 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study 9235377 — intervention group
Group type: COMPARATOR
Intervention: Experimental group
Number of subjects: 58
Study 8234438 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulk laxative plus senna (Agiolax) daily doses 14.8 g
Number of subjects: 30
Study 8234438 — intervention group
Group type: COMPARATOR
Intervention: Lactulose (Levolac) daily doses 20.1 g
Number of subjects: 30
Study 3303178 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% mepivacaine (40 ml)
Number of subjects: 60
Study 3303178 — intervention group
Group type: COMPARATOR
Intervention: 1% prilocaine (40 ml)
Number of subjects: 60
Study 3303178 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 29300876 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD‐TDV (Dengvaxia)
Number of subjects: 31000
Study 29300876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31000
Study 29300876 — intervention group
Group type: EXPERIMENTAL
Intervention: Probable dengue definition
Number of subjects: 31000
Study 27282457 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load resistance training (80% 1RM)
Number of subjects: 15
Study 27282457 — intervention group
Group type: COMPARATOR
Intervention: Low-load resistance training (30% 1RM)
Number of subjects: 15
Study 23559323 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative systemic steroids (100 mg prednisolone per day for 5 days)
Number of subjects: 28
Study 23559323 — intervention group
Group type: COMPARATOR
Intervention: Control group (no steroids)
Number of subjects: 28
Study 23425733 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 813
Study 23425733 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (PHE)
Number of subjects: 813
Study 20845213 — intervention group
Group type: EXPERIMENTAL
Intervention: Instep kick
Number of subjects: 10
Study 20845213 — intervention group
Group type: COMPARATOR
Intervention: Outstep kick
Number of subjects: 10
Study 19047509 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediated learning experience articulated with concept mapping
Number of subjects: 0
Study 19047509 — intervention group
Group type: COMPARATOR
Intervention: Traditional methodology (control group)
Number of subjects: 0
Study 15572391 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee pain induced by injection of hypertonic saline into the infrapatellar fat pad
Number of subjects: 12
Study 15572391 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no knee pain)
Number of subjects: 12
Study 12907822 — intervention group
Group type: EXPERIMENTAL
Intervention: heparin
Number of subjects: 50
Study 12907822 — intervention group
Group type: EXPERIMENTAL
Intervention: therapeutic thrombolysis (tPA)
Number of subjects: 50
Study 12907822 — intervention group
Group type: EXPERIMENTAL
Intervention: hypothermia
Number of subjects: 50
Study 12907822 — intervention group
Group type: COMPARATOR
Intervention: healthy persons
Number of subjects: 50
Study 10976988 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital hip dysplasia (CHD) patients
Number of subjects: 240
Study 10976988 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CHD)
Number of subjects: 240
Study 8862101 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin, 20 to 40 mg once daily
Number of subjects: 4444
Study 8862101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4444
Study 1506543 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management programme as part of an overall fitness programme
Number of subjects: 0
Study 1506543 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation techniques
Number of subjects: 0
Study 1506543 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost evaluation of the stress management programme
Number of subjects: 0
Study 6131914 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-H1 plus anti-H2 (cimetidine, 300 mg t.i.d.)
Number of subjects: 23
Study 6131914 — intervention group
Group type: COMPARATOR
Intervention: anti-H1 plus placebo
Number of subjects: 23
Study 6131914 — intervention group
Group type: COMPARATOR
Intervention: anti-H1 alone
Number of subjects: 23
Study 28974127 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine for 6 weeks
Number of subjects: 52
Study 28449710 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES) 130/0.4, 20 mL·kg‐1
Number of subjects: 60
Study 28449710 — intervention group
Group type: COMPARATOR
Intervention: 5% Human Albumin (HA), 20 mL·kg‐1
Number of subjects: 60
Study 28449710 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HES and HA
Number of subjects: 60
Study 25767382 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful meditation intervention (8-week program)
Number of subjects: 41
Study 25767382 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful meditation intervention (8-week program) with 6 or more classes
Number of subjects: 41
Study 23765203 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of dietary MSG and aspartame (n = 36)
Number of subjects: 72
Study 23765203 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (n = 36)
Number of subjects: 72
Study 21926614 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding (enteral nutrition within 24 hrs of admission)
Number of subjects: 28
Study 21926614 — intervention group
Group type: COMPARATOR
Intervention: Delayed feeding (no enteral nutrition during the first 4 days of admission)
Number of subjects: 28
Study 21926614 — intervention group
Group type: COMPARATOR
Intervention: Delayed feeding
Number of subjects: 28
Study 20698174 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermography assessment in SLE patients
Number of subjects: 34
Study 20698174 — intervention group
Group type: COMPARATOR
Intervention: Thermography assessment in healthy controls
Number of subjects: 34
Study 17563658 — intervention group
Group type: EXPERIMENTAL
Intervention: New TEAM program
Number of subjects: 0
Study 17563658 — intervention group
Group type: COMPARATOR
Intervention: Old TEAM program
Number of subjects: 0
Study 15857746 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular examinations in participating patients (16 patients)
Number of subjects: 65
Study 15857746 — intervention group
Group type: COMPARATOR
Intervention: Non-participating patients (49 patients)
Number of subjects: 65
Study 11922851 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (TES) at sensory threshold
Number of subjects: 32
Study 11922851 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (TES) at 1.5 times motor threshold
Number of subjects: 32
Study 11922851 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (TES) at varying sites
Number of subjects: 32
Study 11783154 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongxinluo capsule (TXLC)
Number of subjects: 64
Study 11783154 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide mononitrate
Number of subjects: 64
Study 7594246 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber supplement
Number of subjects: 0
Study 7594246 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 2148882 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous bolus injection of GM-CSF (0.3-30 micrograms/kg)
Number of subjects: 33
Study 2148882 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus injection of GM-CSF (0.3-30 micrograms/kg)
Number of subjects: 33
Study 2148882 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of GM-CSF (0.3-30 micrograms/kg)
Number of subjects: 33
Study 2148882 — intervention group
Group type: EXPERIMENTAL
Intervention: All methods of administration (subcutaneous bolus, intravenous bolus, intravenous infusion)
Number of subjects: 33
Study 2148882 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of GM-CSF at doses below 3 micrograms/kg
Number of subjects: 33
Study 2148882 — intervention group
Group type: EXPERIMENTAL
Intervention: All methods of administration
Number of subjects: 33
Study 106264 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 X 50 mg bezafibrate daily
Number of subjects: 24
Study 106264 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 X 100 mg bezafibrate daily
Number of subjects: 24
Study 106264 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 X 150 mg bezafibrate daily
Number of subjects: 24
Study 106264 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 X 200 mg bezafibrate daily
Number of subjects: 24
Study 106264 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg bezafibrate daily (optimal dose)
Number of subjects: 24